ANAPTYSBIO, INC
ANAB · XNASCIK 1370053fmd_1EN973P273WE8PBA7GW2WNBPKJManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2015 to Sep 30, 2026, 44 periods
Latest annual · FY2026
Millions- Total revenues
- 235
- Operating income
- 227
- Net income
- (13)
- Free cash flow
- 20
Latest quarter · Q1 FY2027
Millions- Total revenues
- 30
- Operating income
- 20
- Net income
- 4
- Free cash flow
- (26)
Daily close · ANABIEX trades only
Nov 13, 2025 to Nov 11, 2026 · 250 sessions48.87 USD
Built from trades executed at IEX only, one exchange with a small share of US volume. This is not the consolidated tape. The close is the last IEX trade of the session, not the official closing price. Earlier sessions are divided by the later split ratios the API confirmed against IEX prices; dividends are not adjusted. Switch to As traded for the prices as they printed. End of day, not real time: a session is published the day after it trades.
Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. iex.io/legal/hist-data-terms
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2023 to FY2026
- +183.6%
- Revenue, 5 yearsFY2021 to FY2026
- +25.6%
- Net income, 5 yearsFY2021 to FY2026
- n/m
ANAPTYSBIO, INC (ANAB) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2026 | FY2025 | Change | Source |
|---|---|---|---|---|
| Revenue | $234.6 million | $91.3 million | +157% | 10-K 2026-03-03 · proof |
| Operating income | $226.9 million | $66.2 million | +243% | 10-KT 2026-09-21 · proof |
| Net income | -$13.2 million | -$145.2 million | 10-K 2026-03-03 · proof | |
| Cash from operating activities | $19.7 million | -$135.3 million | 10-K 2026-03-03 · proof | |
| Free cash flow | $19.6 million | -$135.7 million | 10-K 2026-03-03 · proof | |
| Total assets | $317 million | $335.3 million | -5.4% | 10-KT 2026-09-21 · proof |
| Total liabilities | $306.4 million | $380 million | -19.4% | 10-KT 2026-09-21 · proof |
| Cash and cash equivalents | $133.8 million | $44.3 million | +202.1% | 10-KT 2026-09-21 · proof |
- What was ANAPTYSBIO, INC (ANAB)'s revenue in fiscal 2026?
- ANAPTYSBIO, INC (ANAB) reported revenue of $234.6 million for fiscal 2026 (the year ended Dec 31, 2025), against $91.3 million the year before (+157%). Source: the 10-K filed with the SEC on Mar 3, 2026. SEC
- What was ANAPTYSBIO, INC (ANAB)'s operating income in fiscal 2026?
- ANAPTYSBIO, INC (ANAB) reported operating income of $226.9 million for fiscal 2026 (the year ended Dec 31, 2025), against $66.2 million the year before (+243%). Source: the 10-KT filed with the SEC on Sep 21, 2026 (restated). SEC
- What was ANAPTYSBIO, INC (ANAB)'s net income in fiscal 2026?
- ANAPTYSBIO, INC (ANAB) reported net income of -$13.2 million for fiscal 2026 (the year ended Dec 31, 2025), against -$145.2 million the year before. Source: the 10-K filed with the SEC on Mar 3, 2026. SEC
- What was ANAPTYSBIO, INC (ANAB)'s cash from operating activities in fiscal 2026?
- ANAPTYSBIO, INC (ANAB) reported cash from operating activities of $19.7 million for fiscal 2026 (the year ended Dec 31, 2025), against -$135.3 million the year before. Source: the 10-K filed with the SEC on Mar 3, 2026. SEC
- What was ANAPTYSBIO, INC (ANAB)'s free cash flow in fiscal 2026?
- ANAPTYSBIO, INC (ANAB) reported free cash flow of $19.6 million for fiscal 2026 (the year ended Dec 31, 2025), against -$135.7 million the year before. Source: the 10-K filed with the SEC on Mar 3, 2026. SEC
- What are ANAPTYSBIO, INC (ANAB)'s total assets?
- As of Jun 30, 2026, ANAPTYSBIO, INC (ANAB) reported total assets of $317 million, against $335.3 million a year earlier (-5.4%). Source: the 10-KT filed with the SEC on Sep 21, 2026. SEC
- What are ANAPTYSBIO, INC (ANAB)'s total liabilities?
- As of Jun 30, 2026, ANAPTYSBIO, INC (ANAB) reported total liabilities of $306.4 million, against $380 million a year earlier (-19.4%). Source: the 10-KT filed with the SEC on Sep 21, 2026. SEC
- What are ANAPTYSBIO, INC (ANAB)'s cash and cash equivalents?
- As of Jun 30, 2026, ANAPTYSBIO, INC (ANAB) reported cash and cash equivalents of $133.8 million, against $44.3 million a year earlier (+202.1%). Source: the 10-KT filed with the SEC on Sep 21, 2026. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:ANAB&period_type=annual&limit=5"Information only, not investment advice.